What Happens Behind the Scenes in Cell Therapy Research for Type 1 Diabetes

Type 1 diabetes occurs when the immune system attacks and destroys the beta cells in the pancreas—the cells responsible for producing insulin. Without insulin, the body cannot regulate blood glucose levels. Cell therapies take a direct approach to this problem: they aim to replace those destroyed cells so the pancreas can produce insulin again.

Vertex Pharmaceuticals is one of several companies pursuing this strategy. Their investigational therapy uses manufactured islet cells—lab-grown versions of the insulin-producing cells found naturally in the pancreas. The goal is to transplant these cells into the body where they can function and restore insulin production.

A central challenge in cell therapy is protecting transplanted cells from the body's immune system, which may attack them just as it attacked the original beta cells. Vertex's current approach requires patients to use immunosuppression—medications that reduce immune system activity—to keep the transplanted cells safe.

This investigational therapy is currently being tested in an ongoing Phase 1/2/3 clinical trial, which means researchers are still evaluating its safety and effectiveness. The immunosuppression requirement is an important trade-off that researchers, patients, and clinicians must carefully consider as this work advances.

The work at Vertex builds on years of foundational research. Dr. Felicia Pagliuca, Senior Vice President of Cell and Genetic Therapy Research at Vertex, was part of the team that discovered how to generate insulin-producing beta cells from stem cells in the laboratory—a crucial step that made cell therapy for Type 1 diabetes possible. She co-founded Semma Therapeutics in 2014 to develop these therapies further, and Vertex acquired the company in 2019.

This long chain of collaboration—spanning Harvard, academic research, and commercial development—demonstrates how breakthroughs in Type 1 diabetes research require sustained effort across institutions and decades of work.

While cell therapies focus on restoring insulin production, the day-to-day reality of living with Type 1 diabetes involves far more than managing a single number. Recent research shows that managing blood glucose during intense physical activity—whether in competitive sports or everyday life—creates both physical and emotional challenges. Athletes with Type 1 diabetes report anxiety around hyperglycemia (high blood sugar) that affects how they adjust insulin doses and approach meals on competition days.

Low blood sugar episodes also take a significant toll. A comprehensive study of adults with diabetes found that hypoglycemia affects sleep quality, creates cognitive burden and worry, limits leisure and exercise, and impacts relationships with partners and loved ones. These findings underscore why therapies that restore consistent insulin production could offer meaningful improvements beyond laboratory measures.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.